The Lantibiotic Lacticin 3147 Prevents Systemic Spread of Staphylococcus aureus in a Murine Infection Model

• Main Authors: Clare Piper, Pat G. Casey, Colin Hill, Paul D. Cotter, R. Paul Ross
• Format: Article
• Language: English
• Published: Hindawi Limited 2012-01-01
• Series: International Journal of Microbiology
• Online Access: http://dx.doi.org/10.1155/2012/806230

The objective of this study was to investigate the in vivo activity of the lantibiotic lacticin 3147 against the luminescent Staphylococcus aureus strain Xen 29 using a murine model. Female BALB/c mice (7 weeks old, 17 g) were divided into groups (n=5) and infected with the Xen 29 strain via the intraperitoneal route at a dose of 1×106 cfu/animal. After 1.5 hr, the animals were treated subcutaneously with doses of phosphate-buffered saline (PBS; negative control) or lacticin 3147. Luminescent imaging was carried 3 and 5 hours postinfection. Mice were then sacrificed, and the levels of S. aureus Xen 29 in the liver, spleen, and kidneys were quantified. Notably, photoluminescence and culture-based analysis both revealed that lacticin 3147 successfully controlled the systemic spread of S. aureus in mice thus indicating that lacticin 3147 has potential as a chemotherapeutic agent for in vivo applications.